Spineway reduces its share capital by reducing the nominal value of the shares

Spineway, a specialist in implants for spinal pathologies, has decided to reduce its share capital. At its meeting of December 4, 2024, the Board of Directors voted, by delegation of the general meeting of March 25, 2024, to reduce the nominal value of the shares from 0.045 euros to 0.002 euros. The share capital thus decreases from 896,018.33 euros to 39,823.04 euros.

This decision aims to facilitate conversions for security holders, following the recent decline in the stock market price. It also prevents compensation provided for in the financing agreement with Negma. The transaction does not affect the stock market value or the number of shares outstanding, which remains at 19,911,518 shares.